Evidence map›Paper›PMID 34641388›Full record

ArticleMolecules (Basel, Switzerland)2021

Heba A El Gizawy, Sylvia A Boshra, Ahmed Mostafa, Sara H Mahmoud, Muhammad I Ismail, Aisha A Alsfouk, Azza T Taher, Ahmed A Al-Karmalawy

Open access · goldAbstract read
In one paragraph

Article in Molecules (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 39 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
39citing papers in PubMed, 2 pooled it
20.7field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

39 citing papers in PubMed, 2 syntheses or guidelines pooled it, 81 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Integrated Evaluation ofPharmaceuticals (Basel, Switzerland) · 2026
    Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. In vitro study on efficacy of SKF7BMC complementary medicine and therapies · 2024
    Article
  10. Article
  11. Biological evaluation, docking studies, andJournal of enzyme inhibition and medicinal chemistry · 2023
    Article
  12. Article
  13. Phytochemical profiling ofSaudi pharmaceutical journal : SPJ : the official publication of the Saudi Pharmaceutical Society · 2023
    Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 2 countries.

Heba A El GizawyDepartment of Pharmacognosy, Faculty of Pharmacy, October 6 University (O6U), October 6 City, Giza 12585, Egypt.
Sylvia A BoshraDepartment of Biochemistry, Faculty of Pharmacy, October 6 University (O6U), October 6 City, Giza 12585, Egypt.
Ahmed MostafaCenter of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Giza 12622, Egypt.ORCID 0000-0002-2878-5714
Sara H MahmoudCenter of Scientific Excellence for Influenza Viruses, National Research Centre (NRC), Dokki, Giza 12622, Egypt.
Muhammad I IsmailDepartment of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, Al-Sherouk City, Cairo-Suez Desert Road, Cairo 11837, Egypt.ORCID 0000-0003-2562-4357
Aisha A AlsfoukDepartment of Pharmaceutical Sciences, College of Pharmacy, Princess Nourah bint Abdulrahman University, Riyadh 84428, Saudi Arabia.ORCID 0000-0003-4497-5013
Azza T TaherDepartment of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo 11562, Egypt.
Ahmed A Al-KarmalawyDepartment of Pharmaceutical Medicinal Chemistry, Faculty of Pharmacy, Horus University-Egypt, New Damietta 34518, Egypt.ORCID 0000-0002-8173-6073
National Research Centre · EGOctober 6 University · EGBritish University in Egypt · EGCairo University · EGDamietta University · EGPrincess Nourah bint Abdulrahman University · SA

Funding

Princess Nourah Bint Abdulrahman University Fast-tract Research Funding program.
6 · The paper itself

Abstract

In response to the urgent need to control Coronavirus disease 19 (COVID-19), this study aims to explore potential anti-SARS-CoV-2 agents from natural sources. Moreover, cytokine immunological responses to the viral infection could lead to acute respiratory distress which is considered a critical and life-threatening complication associated with the infection. Therefore, the anti-viral and anti-inflammatory agents can be key to the management of patients with COVID-19. Four bioactive compounds, namely ferulic acid

Indexed as

COVID-19 Drug TreatmentPimentaAnimalsAnti-Inflammatory AgentsAntiviral AgentsChlorocebus aethiopsChlorogenic AcidCoumaric AcidsGallic AcidHumansMaleMolecular Docking SimulationMolecular Dynamics SimulationPlant ExtractsRatsRutinAnti-Inflammatory AgentsAntiviral AgentsChlorogenic AcidCoumaric Acidsferulic acidGallic AcidPlant ExtractsRutinanti-SARS-CoV-2docking and dynamics simulationsin vitro and in vivo studiesPimentarutin

Identifiers

PMID34641388
PMCPMC8510437
OpenAlexW3203915129

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.